{"version":"1.0","type":"rich","provider_name":"Buzzsprout","provider_url":"https://www.buzzsprout.com","author_url":"https://www.asxbriefs.au/2335647","width":500,"thumbnail_width":600,"thumbnail_height":600,"title":"ACTINOGEN MEDICAL LTD (ACW) - Revolutionizing Mental Health Treatment: CEO Steve Gourlay on Breakthrough Xanamem Drug, Phase 2 Trial Success, and Future Implications","author_name":"ASX BRIEFS","html":"<iframe src=\"https://www.asxbriefs.au/2335647/episodes/15839146-actinogen-medical-ltd-acw-revolutionizing-mental-health-treatment-ceo-steve-gourlay-on-breakthrough-xanamem-drug-phase-2-trial-success-and-future-implications?client_source=oembed&amp;iframe=true\" width=\"100%\" height=\"200\" frameborder=\"0\" scrolling=\"no\" loading=\"lazy\" title=\"ASX BRIEFS, ACTINOGEN MEDICAL LTD (ACW) - Revolutionizing Mental Health Treatment: CEO Steve Gourlay on Breakthrough Xanamem Drug, Phase 2 Trial Success, and Future Implications\"></iframe>","height":200,"thumbnail_url":"https://www.asxbriefs.au/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTExODY0Njk5LCJwdXIiOiJibG9iX2lkIn19--4950efcd19cc31898dfe84e6ee734b99c57f64b9/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzYwMCw2MDAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--0b154cb6b88107719b1a277923d35676ba5519cc/asx%20briefs.jpg"}